文献速递眼底病与葡萄膜炎

基于iTRAQ LC-MS/MS蛋白组学探索增生性糖尿病视网膜病变治疗新靶点

[New exploration of treatment target for proliferative diabetic retinopathy based on iTRAQ LC-MS/MS Proteomics].
PubMed 文献 · Zhonghua Yan Ke Za Zhi · 2019-01-01

该实验研究收集28例增生性糖尿病视网膜病变(PDR)患者和4例玻璃体混浊患者的玻璃体液,采用iTRAQ标记联合LC-MS/MS定量蛋白组学筛选差异表达蛋白。共鉴定26个差异蛋白(7个上调、19个下调),涉及Chemerin、Sema 4B、ApoB和HSP70等,KEGG分析显示Akt、PI3K及HIF-1α信号通路存在差异。作者认为Chemerin、Sema 4B、ApoB和HSP70可能成为PDR治疗靶点。

要点

  • PDR玻璃体液中鉴定出26个差异蛋白,其中7个上调、19个下调。
  • Chemerin、Sema 4B、HSP70在PDR组表达下调,ApoB在PDR组表达上调。
  • KEGG分析显示Chemerin-Akt、Sema 4B-PI3K及HIF-1α信号通路在两组间存在差异。

核心结论

  • Chemerin、Sema 4B、ApoB和HSP70可能成为PDR防治的新靶点。
  • Chemerin和ApoB加速PDR发展,Sema 4B和HSP70对PDR患者视网膜神经血管起保护作用。

研究设计与样本

  • 实验研究,收集2016年9月至2017年11月在天津医科大学眼科医院就诊的PDR患者28例和玻璃体混浊患者4例的玻璃体液。
  • PDR患者按随机数字表法分为2个PDR组,每组14例;玻璃体混浊患者随机分为2个对照组,每组2例。
  • PDR患者与玻璃体混浊患者的平均年龄分别为52和64岁。
  • 每组样本混合后提取蛋白,行iTRAQ标记,经LC-MS/MS分析后进行差异蛋白分析及GO和KEGG富集分析。

主要发现

  • PDR玻璃体液中鉴定出26个差异表达蛋白,包括7个上调蛋白和19个下调蛋白(P<0.05)。
  • Chemerin在PDR1组=85.0、PDR2组=83.0,对照1组=119.6、对照2组=120.2,FC=0.710,P=0.001。
  • Sema 4B在PDR1组=64.4、PDR2组=68.8,对照1组=135.4、对照2组=146.0,FC=0.473,P=0.023。
  • ApoB在PDR1组=104.4、PDR2组=106.6,对照1组=89.0、对照2组=85.3,FC=1.211,P=0.024。
  • HSP70在PDR1组=69.3、PDR2组=75.0,对照1组=137.7、对照2组=138.3,FC=0.523,P=0.026。

关键数值与推荐

  • GO功能富集分析显示差异基因功能涉及细胞代谢过程、有机氮化合物代谢过程、碳水化合物衍生物代谢过程、转移酶活化和跨膜信号受体活化等。
  • KEGG通路富集分析显示Chemerin参与的Akt信号通路、Sema 4B参与的PI3K信号通路及HIF-1α信号通路在2个组玻璃体液间存在差异。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To identify differentially expressed proteins between the patients with proliferative diabetic retinopathy (PDR) and vitreous floaters, and explore treatment target for PDR based on isobaric tags for relative and absolute quantification (iTRAQ) LC-MS/MS Proteomics. Method: Vitreous samples were collected from 28 eyes of patients with PDR and 4 eyes with vitreous floaters, which served as controls. For quantitative proteomics, vitreous samples were combined and proteins extracted and labeled with iTRAQ peptide-tagging reagents. Samples were fractionated by liquid chromatography (LC), analyzed by tandem mass spectrometry (MS/MS) and Gene Ontology (GO) analyses performed on differentially expressed proteins identified in the PDR samples. Results: In the PDR vitreous, 26 proteins were identified that were differentially expressed when compared to the controls. Of these, 7 showed a significant increase (P<0.05) and 19 a significant decrease (P<0.05)in expression in PDR patients. These included some high abundance proteins including Retinoic acid receptor reactive protein 2 (PDR 1=85.0, PDR 2=83.0, Control 1=119.6, Control 2=120.2, FC=0.710, P=0.001), Semaphorin-4B(PDR 1=64.4, PDR 2=68.8, Control 1=135.4, Control 2=146.0, FC=0.473, P=0.023), Apolipoprotein B (PDR 1=104.4, PDR 2=106.6, Control 1=89.0, Control 2=85.3, FC=1.211, P=0.024), and Heat shock protein 70 (PDR 1=69.3, PDR 2=75.0, Control 1=137.7, Control 2=138.3, FC=0.523, P=0.026), which are closely related to the pathological mechanism of PDR. GO analysis clustered the differentially expressed genes into three major functional domains: Biological Processes, Molecular Function and Cellular Component. Differential gene expression was found in the categories of cellular metabolism, organonitrogen compound and carbohydrate derivative metabolic processes, transferase activity and transmembrane signaling receptor activity. KEGG Pathway analysis indicate that Chemerin signaling through Akt, Sema4B signaling via PI3K, and HIF-1α signal pathways were all altered in the PDR samples. Conclusions: In this study we identified variations in expression of genes extensively involved in key biological processes in the retina including neovascularization, cellular metabolism and transmembrane signaling, which provide new insights into the pathophysiology of PDR. Extracellular matrix was degraded and endothelial cell migration was induced by Chemerin, in addition, the destruction of blood-retinal barrier and neuronal apoptosis were induced by ApoB. Chemerin and ApoB accelerated the development of PDR. Sema 4B participated in vascular protection, HSP70 conducted anti-apoptosis. These two cytokines protected the retinal neurovascular in PDR patients. Therefore, Chemerin, Sema 4B, ApoB and HSP70 may be the treatment target for PDR. (Chin J Ophthalmol, 2019, 55:769-776). 目的: 探讨采用同位素标记相对和绝对定量(iTRAQ)技术的蛋白组学分析筛选增生性糖尿病视网膜病变(PDR)患者与玻璃体混浊患者玻璃体液之间差异表达蛋白的可行性,寻找PDR防治的新靶点。 方法: 实验研究。收集2016年9月至2017年11月在天津医科大学眼科医院就诊的PDR的患者28例,随机数字表法随机分为2个PDR组,每组14例;另将诊断为玻璃体混浊的患者4例作为对照组,随机分为2个对照组,每组2例。PDR患者与玻璃体混浊患者的平均年龄分别为52和64岁。将每组患者的样本混合后提取蛋白,行iTRAQ标记,根据液相质谱-串联质谱检测(LC-MS/MS)分析结果,行差异蛋白分析及相应蛋白基因本体论(GO)数据库功能富集及京都基因与基因组(KEGG)数据库通路图显著性富集分析。对玻璃体液蛋白谱的相对定量结果进行独立样本t检验,结合差异倍数(FC)和P值判定蛋白表达量变化。 结果: 根据不同患者的玻璃体液蛋白表达谱信息,发现其间共存在26个差异表达蛋白,PDR包括7个上调蛋白和19个下调蛋白,如视黄酸受体反应蛋白2(Chemerin)(PDR1组=85.0,PDR2组=83.0,对照1组=119.6,对照2组=120.2,FC=0.710,P=0.001)、轴突生长导向因子4B(Semaphorin 4B,Sema 4B)(PDR1组=64.4,PDR2组=68.8,对照1组=135.4,对照2组=146.0,FC=0.473,P=0.023)、载脂蛋白B(Apolipoprotein,ApoB)(PDR1组=104.4,PDR2组=106.6,对照1组=89.0,对照2组=85.3,FC=1.211,P=0.024)和热休克蛋白70(Heat shock protein 70,HSP70)(PDR1组=69.3,PDR2组=75.0,对照1组=137.7,对照2组=138.3,FC=0.523,P=0.026)与PDR的发生发展密切相关。通过对差异蛋白的GO功能显著性富集分析显示,差异基因的功能划分为生物过程、分子功能及细胞组分形成3大板块。差异表达基因功能涉及细胞代谢过程、有机氮化合物代谢过程、碳水化合物衍生物代谢过程及转移酶活化、跨膜信号受体活化等诸多方面。KEGG Pathway显著性富集分析结果显示,Chemerin参与的蛋白激酶B(Akt)信号通路,Sema 4B参与的磷脂酰肌醇3-激酶(phosphoinositide 3-kinase,PI3K)信号通路,及缺氧诱导因子-1α(HIF-1α)信号通路在2个组玻璃体液间存在差异。 结论: 应用iTRAQ标记结合LC-MS/MS定量蛋白组学为筛选有生物学意义的差异表达蛋白提供良好的平台,进而为差异蛋白定量检测及低丰度差异蛋白筛选奠定基础。Chemerin、Sema 4B、ApoB和HSP70可作为PDR防治的新靶点。(中华眼科杂志,2019,55:769-776).

来源:Zhonghua Yan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wen DJ, Ren XJ, Dong LJ, et al. [New exploration of treatment target for proliferative diabetic retinopathy based on iTRAQ LC-MS/MS Proteomics]. Zhonghua Yan Ke Za Zhi. 2019. PMID: 31607066. doi:10.3760/cma.j.issn.0412-4081.2019.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。